文献速递心脑血管急症重症综合管理与镇静镇痛

识别疫苗诱导的免疫性血栓性血小板减少症

Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论腺病毒载体COVID-19疫苗接种后5-30天出现血栓、血小板减少和D-二聚体升高,应疑诊VITT,立即用非肝素抗凝和大剂量IVIG治疗。

本文综述了疫苗诱导的免疫性血栓性血小板减少症(VITT)的发病机制、临床表现、诊断和治疗。VITT多在腺病毒载体COVID-19疫苗接种后5-30天出现,表现为异常部位血栓(脑静脉窦血栓、内脏静脉血栓)或常见血栓(动脉卒中、肺栓塞、深静脉血栓),常伴严重血小板减少,多数患者有弥散性血管内凝血。其机制为疫苗触发抗血小板因子4免疫球蛋白G形成并激活血小板,临床类似自身免疫性肝素诱导的血小板减少症。依据血栓、血小板减少和D-二聚体升高早期识别很重要,治疗为大剂量静脉免疫球蛋白联合非肝素抗凝。

要点

  • 腺病毒载体COVID-19疫苗接种后5-30天出现持续头痛、神经症状/体征、腹痛、呼吸困难或肢体疼痛/肿胀,必须查血小板计数和D-二聚体并做血栓影像。
  • VITT常表现为异常血栓(脑静脉窦血栓、内脏静脉血栓)或常见血栓(动脉卒中、肺栓塞、深静脉血栓),伴严重血小板减少,多数有弥散性血管内凝血。
  • 疑似VITT时应在启动治疗(非肝素抗凝、静脉免疫球蛋白)的同时送检确诊:血小板因子4/聚阴离子酶联免疫吸附试验和血小板因子4增强的血小板活化试验。
  • VITT治疗为大剂量静脉免疫球蛋白联合非肝素抗凝,早期识别基于血栓(有时出血)、血小板减少和D-二聚体升高。
  • VITT是疫苗接种的严重并发症,无法预见或预防。

适用人群与场景

  • 腺病毒载体COVID-19疫苗接种后5-30天的患者,出现持续头痛、神经症状/体征、腹痛、呼吸困难或肢体疼痛/肿胀时适用。

诊断标准与关键阈值

  • 诊断依据:疫苗接种后5-30天窗口内出现血栓(有时出血)、血小板减少和D-二聚体升高。
  • 确认诊断检查:血小板因子4/聚阴离子酶联免疫吸附试验;血小板因子4增强的血小板活化测试。

处置流程与药物剂量

  • 第一步:对疫苗接种后5-30天出现持续头痛、神经症状/体征、腹痛、呼吸困难或肢体疼痛/肿胀的患者,测量血小板计数和D-二聚体,并做血栓影像。
  • 第二步:在启动治疗的同时送检确诊VITT(血小板因子4/聚阴离子酶联免疫吸附试验;血小板因子4增强的血小板活化测试)。
  • 第三步:治疗用非肝素抗凝联合大剂量静脉免疫球蛋白(原文未给出具体剂量、单位、途径、频次或疗程)。

红旗征与不能漏的情况

  • 疫苗接种后5-30天出现持续头痛、神经症状/体征、腹痛、呼吸困难或肢体疼痛/肿胀,需立即查血小板计数、D-二聚体和血栓影像。
  • 血栓(有时出血)伴血小板减少和D-二聚体升高,提示VITT,需立即启动非肝素抗凝和静脉免疫球蛋白治疗。

研究设计与关键结果

  • 本文为综述,检索PubMed、Scopus、Web of Science和Google Scholar,纳入与COVID-19、疫苗和血栓相关的文献。
  • VITT多在腺病毒载体COVID-19疫苗接种后5-30天出现,表现为异常血栓(脑静脉窦血栓、内脏静脉血栓)或常见血栓(动脉卒中、肺栓塞、深静脉血栓),常伴严重血小板减少。
  • 多数VITT患者有弥散性血管内凝血;机制为疫苗触发抗血小板因子4免疫球蛋白G形成并激活血小板,临床类似自身免疫性肝素诱导的血小板减少症。

证据类型、等级与局限

  • 证据类型:综述;原文未给出证据等级或推荐强度。
  • 局限:原文未提及。

对床旁实践的改变

  • 对腺病毒载体COVID-19疫苗接种后5-30天出现持续头痛、神经症状/体征、腹痛、呼吸困难或肢体疼痛/肿胀的患者,应常规测量血小板计数和D-二聚体并做血栓影像。
  • 疑似VITT时,不应等待确诊结果,应同时启动非肝素抗凝和大剂量静脉免疫球蛋白治疗,并送检确诊试验。
  • VITT无法预见或预防,早期识别基于血栓(有时出血)、血小板减少和D-二聚体升高的组合。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: Vaccine-induced immune thrombotic thrombocytopenia is an unexpected consequence of the coronavirus disease 2019 pandemic era. We reviewed the pathogenesis, clinical presentation, diagnosis, and treatment of this rare side effect.

DATA SOURCES: Online search of published medical literature through PubMed, Scopus, Web of Science, and Google Scholar using the terms "COVID-19," "vaccine," "thrombosis" was performed.

STUDY SELECTION: Articles were chosen for inclusion based on their relevance to coronavirus disease 2019, vaccine, and thrombosis.

DATA SYNTHESIS: Vaccine-induced immune thrombotic thrombocytopenia manifests most often as unusual thromboses (cerebral venous sinus thrombosis, splanchnic vein thrombosis) but sometimes also "usual" thromboses (arterial stroke, pulmonary embolism, deep-vein thrombosis), with oftentimes severe thrombocytopenia, that becomes clinically evident 5-30 days after adenovirus-vectored coronavirus disease 2019 vaccine administration. Most patients have disseminated intravascular coagulation. These features are the result of vaccine-triggered formation of anti-platelet factor 4 immunoglobulin G that activate platelets, clinically mimicking autoimmune heparin-induced thrombocytopenia. Early recognition based on thrombosis (sometimes, hemorrhage), thrombocytopenia, and d-dimer elevation within the day 5-30 postvaccine "window" is important given treatment with high-dose IV immunoglobulin plus nonheparin anticoagulation.

CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5-30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4-enhanced platelet activation testing) as treatment is initiated (nonheparin anticoagulation, IV immunoglobulin).

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Iba T, Levy JH, Warkentin TE, et al. Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Med. 2022. PMID: 34259661. doi:10.1097/CCM.0000000000005211

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。